Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study

Benatar, M., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., Otto, M., Farahany, N. A., Harrington, E. A., Chen, W., Mitchell, A. A., Ferguson, T., Chew, S., Gedney, L., Oakley, S., Heo, J., Chary, S., Fanning, L., Graham, D., Sun, P., … Fradette, S. (2022). Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 19(4), 1248–1258. https://doi.org/10.1007/s13311-022-01237-4
Authors:
Michael Benatar
Joanne Wuu
Peter M. Andersen
Robert C. Bucelli
Jinsy A. Andrews
Markus Otto
Nita A. Farahany
Elizabeth A. Harrington
Weiping Chen
Adele A. Mitchell
Toby Ferguson
Sheena Chew
Liz Gedney
Sue Oakley
Jeong Heo
Sowmya Chary
Laura Fanning
Danielle Graham
Peng Sun
Yingying Liu
Janice Wong
Stephanie Fradette
Affiliated Authors:
Jinsy A. Andrews
Elizabeth A. Harrington
Author Keywords:
sod1-als
neurofilament
genetic testing
pre-fals
phenoconversion
Publication Type:
Article
Unique ID:
10.1007/s13311-022-01237-4
PMID:
Publication Date:
Data Source:
Scopus

Record Created: